Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02090959 · ClinicalTrials.gov registry record · Phase 3
An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy
A Phase 3 study, sponsored by PTC Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 219
- Enrollment target
NCT02090959 is a Phase 3 study that was terminated before completion, run by PTC Therapeutics. The registered enrollment target is 219 participants.
The verdict
NCT02090959, a Phase 3 study, was terminated before completion, sponsored by PTC Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 219 participants
- Enrollment target
Study Summary
The primary objective of this study is to obtain long term safety data of ataluren in male participants with nonsense mutation dystrophinopathy (who participated and completed a previous Phase 3 study of ataluren \[PTC124-GD-020-DMD {NCT01826487}\]) to augment the overall safety database. Screening and baseline procedures are structured to avoid a gap in treatment between the double-blind study (PTC124-GD-020-DMD) and this extension study. This study may be further extended by amendment until either ataluren becomes commercially available or the clinical development of ataluren in duchenne muscular dystrophy (DMD) is discontinued.
Interventions
- DRUG Ataluren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2014-03-20 |
| Est. Completion | 2018-06-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02090959
The ClinicalTrials.gov registry entry for NCT02090959 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 219 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PTC Therapeutics, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ataluren is the first listed.
NCT02090959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02090959 about?
NCT02090959 is a clinical study titled "An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy". The primary objective of this study is to obtain long term safety data of ataluren in male participants with nonsense mutation dystrophinopathy (who participated and completed a previous Phase 3 study of ataluren \[PTC124-GD-020-DMD {NCT01826487}\]) to augment the overall safety database. Screening ...
What is the current status of trial NCT02090959?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 219 participants. The study started on 2014-03-20. Estimated completion is 2018-06-12.
What interventions are being tested in trial NCT02090959?
The interventions under investigation include: Ataluren (DRUG).
Who is sponsoring clinical trial NCT02090959?
This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.